Regeneron Pharmaceuticals (REGN) revenue
Regeneron Pharmaceuticals (REGN) reported revenue of $14.34B in fiscal 2025 (the year ended December 31, 2025). That is 1.0% higher than the $14.20B of fiscal 2024. Figures as of 18 Nov 2026, 11:49 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2025
- $14.34B
- Change on fiscal 2024
- +1.0%
- Growth, 5 years
- +11.0% a year
- Growth, 10 years
- +13.3% a year
- Highest on record
- $16.07Bfiscal 2021
- Lowest on record
- $238.46Mfiscal 2008
- Fiscal years on record
- 182008–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Regeneron Pharmaceuticals revenue, in more detail
Over the five fiscal years to 2025 revenue grew at a compound 11.0% a year; over ten years the rate was 13.3% a year. Across the 18 fiscal years on record (2008–2025), the highest was $16.07B in fiscal 2021 and the lowest $238.46M in fiscal 2008.
Revenue by fiscal year
Regeneron Pharmaceuticals revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2025 | $14.34B | 1.0% up | |
| 2024 | $14.20B | 8.3% up | |
| 2023 | $13.12B | 7.8% up | |
| 2022 | $12.17B | 24.3% down | |
| 2021 | $16.07B | 89.1% up | |
| 2020 | $8.50B | 29.6% up | |
| 2019 | $6.56B | 27.4% up | |
| 2018 | $5.15B | 12.4% down | |
| 2017 | $5.87B | 20.8% up | |
| 2016 | $4.86B | 18.4% up | |
| 2015 | $4.10B | 45.5% up | |
| 2014 | $2.82B | 34.0% up | |
| 2013 | $2.10B | 52.7% up | |
| 2012 | $1.38B | 209.2% up | |
| 2011 | $445.82M | 2.9% down | |
| 2010 | $459.07M | 21.0% up | |
| 2009 | $379.27M | 59.1% up | |
| 2008 | $238.46M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Revenue at health care companies of similar size
| Company | Revenue | Fiscal year |
|---|---|---|
| Moderna MRNA | $1.92B | 2025 |
| CVS Health CVS | $402.07B | 2025 |
| HCA Healthcare HCA | $75.60B | 2025 |
| GSK GSK | £32.67B | 2025 |
| Regeneron Pharmaceuticals REGN | $14.34B | 2025 |
| Elevance Health ELV | $199.13B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Regeneron Pharmaceuticals, figure by figure
- Regeneron Pharmaceuticals market cap
- Regeneron Pharmaceuticals earnings
- Regeneron Pharmaceuticals earnings per share (EPS)
- Regeneron Pharmaceuticals P/E ratio
- Regeneron Pharmaceuticals P/S ratio
- Regeneron Pharmaceuticals P/B ratio
- Regeneron Pharmaceuticals free cash flow
- Regeneron Pharmaceuticals operating margin
- Regeneron Pharmaceuticals dividend
- Regeneron Pharmaceuticals shares outstanding
- Regeneron Pharmaceuticals total debt
- Regeneron Pharmaceuticals cash on hand
- Regeneron Pharmaceuticals total assets
- Regeneron Pharmaceuticals return on equity (ROE)
- Regeneron Pharmaceuticals return on invested capital (ROIC)
Regeneron Pharmaceuticals (REGN) overview: price, valuation and scorecardAll health care companies by market value
Regeneron Pharmaceuticals revenue: questions and answers
What is Regeneron Pharmaceuticals's revenue?
Regeneron Pharmaceuticals (REGN) reported revenue of $14.34B in fiscal 2025 (the year ended December 31, 2025). That is 1.0% higher than the $14.20B of fiscal 2024.
What is the growth rate of Regeneron Pharmaceuticals's revenue?
Over the five fiscal years to 2025 revenue grew at a compound 11.0% a year; over ten years the rate was 13.3% a year.
What are the highest and lowest revenue figures on record for Regeneron Pharmaceuticals?
Across the 18 fiscal years on record (2008–2025), the highest was $16.07B in fiscal 2021 and the lowest $238.46M in fiscal 2008.
How is Regeneron Pharmaceuticals's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Regeneron Pharmaceuticals it is on record here for 18 fiscal years, 2008 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Regeneron Pharmaceuticals (REGN) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/REGN/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.